Keywords: Johnson & Johnson, Zytiga, Prostate cancer, IQWiG, Germany

J&J’s Zytiga offers considerable added benefit in certain patients

Article | 09 January 2012

Print This

US health care giant Johnson & Johnson’s Zytiga (abiraterone) was approved in Europe last fall for men with ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in